What: Shares ofIGI Laboratories , a specialty generic pharmaceuticalcompany, soared more than 22% higher this morning after the company reported second quarter earnings last night.
So what: Revenue for the quarter jumped 37% year-over-year to $8.9 million,slightly ahead of the $8.89 million that analysts were expecting. On a GAAP basis, net loss for the quarter was -$0.04 per share, which was well ahead of the -$0.08 loss that analysts were expecting.
Continue Reading Below
The company reaffirmed revenue guidance for the full year to land between $35 and $40 million and also expects that gross margins will improve with each passing quarter. This should allow the company to approach a break-even operating margin by the fourth quarter.
In addition, the company is planning to submit up to 20 abbreviated new drug applications, or ANDAs, to the FDA by the end of the year. An ANDA is an application for a generic drug approval for an existing licensed medication or drug.
Now what: IGI was able to submit 6 new ANDA submissions to the FDA for approval during the quarter, bringing their total to 28 ANDAs currently pending approval. Combined, the company estimates that these 28 generic drugs represent a $1.2 billion marketopportunity, which is a huge increase from the $702 million opportunity that the company was previously targeting from their ANDA submissions just last quarter.
Although ANDAs can take a long time to get through the FDA, I think investors were right to cheer the news today, as a $1.2 billion market opportunity is simply massive for a company that is estimating full year revenue of just $35 to $40 million.
With more than $150million in cash on the balance sheet, the company appears to have plenty of capital to fund its research and development efforts needed to complete the additional ANDA filings. If IGI can manage to reach a break-even operating margin by the end of the year, it should put the company on solid financial footing, which could make the stock a very interesting investment opportunity, even after today's huge move.
The article Why Shares of IGI Laboratories, Inc. Soared Today originally appeared on Fool.com.
Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.